摘要
目的观察康莱特联合多西他赛(多西紫杉醇)治疗晚期复发非小细胞肺癌患者的疗效及其对生活质量的影响。方法对82例有病理或细胞学诊断并有可测量病灶、多程化疗后复发的晚期非小细胞肺癌(NSCLC)患者采用完全随机分组的方法,分为康莱特联合多西他赛组41例(康莱特注射液100ml,每日一次静点,连用10～20天,多西他赛35mgm2静脉滴注,第1,8天,21天为1周期,平均2周期),多西他赛单药组41例(多西他赛用法同前)。结果康莱特联合多西他赛组和多西他赛单药组有效率分别为17.1%和12.2%(P>0.05);临床受益率(CR+PR+SD)康莱特联合多西他赛组高于多西他赛单药组(82.9%vs63.4%),且有显著性差异(P<0.05)。二组的中位生存期分别为10.5个月和9.8个月,无显著性差异。康莱特联合多西他赛组病人化疗时生活质量优于多西他赛单药组,Ⅱ度～Ⅲ度骨髓抑制率下降,P<0.05。结论康莱特联合多西他赛治疗复发晚期非小细胞肺癌能增加疗效,改善病人生活质量,并具有保护骨髓的功能。
Objective To observe the clinical effect of Kanglaite combine docetaxel in the relapse of advanced non - small cell lung cancer and the effect on quality of life during treatment. Methods Eighty - two patients of advanced non - small cell lung cancer, with pathology or cytology proved, had received former chemotherapy and relapsed. 82 patients were randomly divided into two groups （41 cases in Kanglaite combined with docetaxel group and 41 cases in docetaxel chemotherpy group）. All patients received docetaxel 35mg/m^2 on day 1 and 8, with and without kanglaite. Results The RR of two groups werel7.1%, 12.2%, Kanglaite combined do- cetaxel group more effective, but P 〉 0.05. The CR ＋ PR ＋ SD of two groups were 82.9% and 63.4%, and P 〈 0.05, Kanglaite group more effective. The rate of ache relieveing, grade of KPS and grade of weight were increased signifcantly in Kanglaite group （ P 〈 0.05）. The marrow toxicity reduced in Kanglaite group （ P 〈0.05）. Conclusion Kanglaite combined docetaxel can improve the quality of life, curative effect is good, and relieve marrow toxicity of chemotherapy.
出处
《癌症进展》
2006年第4期362-365,共4页
Oncology Progress
关键词
康莱特
多西他赛
非小细胞肺癌
药物疗法
Kanglaite docetaxel non- small cell lung cancer drug therapy
